Novogenia Launches Expanded MGT Plus Methylation Test in U.S.

Novogenia AG, a key player in the field of human genetics, has announced the U.S. launch of its MGT Plus methylation test. This product, developed in collaboration with 10X Health, aims to extend their offerings and enhance their presence in genetic analysis and longevity. The MGT Plus test examines 27 genes to provide a detailed view of methylation processes across multiple biological pathways.

These pathways include energy and nutrient metabolism, stress regulation, and cellular health. The broader analysis offered by the test facilitates more precise personal health strategies, highlighting an advancement in preventive care. The direct-to-consumer testing market, particularly genetic testing, is growing rapidly and expected to exceed $16 billion by 2033.

North America remains a significant player in this market, previously accounting for 50% of global sales by 2025. This launch underscores Novogenia's commitment to leveraging innovative science on an international scale.